 | Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at JPMorgan Chase & Co.
marketbeat.com - January 6 at 8:26 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at Piper Sandler
marketbeat.com - December 16 at 7:07 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Buy" at Zacks Investment Research
marketbeat.com - November 14 at 5:00 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Zacks Investment Research to Hold
marketbeat.com - November 12 at 8:56 AM |
| HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $33.00
marketbeat.com - September 18 at 7:30 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by BidaskClub to "Buy"
marketbeat.com - August 25 at 5:29 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Lowered to "Sell" at Zacks Investment Research
marketbeat.com - August 13 at 7:03 AM |
 | Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 7.1%
americanbankingnews.com - January 14 at 8:50 PM |
| Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 7.5%
americanbankingnews.com - January 7 at 7:42 PM |
 | Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings
finance.yahoo.com - January 7 at 11:15 AM |
|
| Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at JPMorgan Chase & Co.
americanbankingnews.com - January 6 at 8:20 AM |
| Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:57 AM |
| Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.3%
americanbankingnews.com - December 29 at 7:44 PM |
| MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
finance.yahoo.com - December 29 at 1:03 PM |
| Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
finance.yahoo.com - December 16 at 7:45 AM |
| Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 15 at 8:17 PM |
| Is PTGX A Good Stock To Buy Now?
finance.yahoo.com - December 13 at 12:39 PM |
 | Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
prnewswire.com - December 10 at 11:57 PM |
| Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 10 at 5:18 PM |
| Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
finance.yahoo.com - December 7 at 11:34 AM |
| Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
finance.yahoo.com - December 6 at 3:30 PM |
| Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
finance.yahoo.com - December 2 at 9:24 AM |
| Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
finance.yahoo.com - November 30 at 7:21 AM |
| Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
finance.yahoo.com - November 25 at 9:24 AM |
| Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
finance.yahoo.com - November 11 at 6:00 PM |
| Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 4 at 10:02 PM |
| Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 4 at 5:02 PM |
| Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
finance.yahoo.com - November 4 at 12:01 PM |
|
 | Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program
seekingalpha.com - October 30 at 9:34 AM |
| Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
finance.yahoo.com - October 29 at 6:32 PM |
| Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - October 28 at 1:58 PM |
| Protagonist Therapeutics's lead asset an Orphan Drug in Europe for a type of blood cancer
seekingalpha.com - October 21 at 8:05 AM |
| Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
finance.yahoo.com - October 21 at 8:05 AM |
| Protagonist Therapeutics, Inc. (PGF.SG)
au.finance.yahoo.com - October 11 at 5:05 PM |
| Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 10 at 9:01 PM |
| Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar
finance.yahoo.com - September 2 at 7:43 PM |
| Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM |
| Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM |
 | Protagonist Therapeutics Inc (NMQ:PTGX) price about to hit new 52-week high
uk.finance.yahoo.com - August 20 at 10:01 AM |
| Protagonist Appoints Sarah O'Dowd to Board of Directors
prnewswire.com - August 13 at 7:25 PM |
| Protagonist Appoints Sarah O'Dowd to Board of Directors
finance.yahoo.com - August 13 at 7:25 PM |
 | Protagonist ramps up construction on Lower South End brewery
bizjournals.com - August 7 at 6:56 PM |
| Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 6 at 10:49 PM |
| Protagonist EPS misses by $0.02, beats on revenue
seekingalpha.com - August 6 at 5:46 PM |
| Protagonist Therapeutics: 2Q Earnings Snapshot
finance.yahoo.com - August 6 at 5:46 PM |
| Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 6 at 5:46 PM |
 | Protagonist Therapeutics, Inc. Common Stock
www.fool.com - August 2 at 12:59 AM |
| Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
finance.yahoo.com - July 29 at 3:04 PM |
| Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?
finance.yahoo.com - June 28 at 1:24 AM |
| Why Protagonist Should Be On Your Radar After Latest Trial Update
seekingalpha.com - June 26 at 7:34 AM |
 | Stock Alert: Protagonist Therapeutics Up 10% As Hepcidin Mimetic PTG-300 Gets Orphan Drug Status
www.nasdaq.com - June 18 at 12:20 PM |
| Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - June 16 at 10:39 PM |
| Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning
seekingalpha.com - June 10 at 12:59 PM |
| Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
finance.yahoo.com - June 4 at 11:03 AM |
 | Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
www.bloomberg.com - May 26 at 5:56 PM |
| Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts
finance.yahoo.com - May 18 at 10:48 AM |
| Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 3:54 AM |
